{"name":"Elliot Israel, MD","slug":"elliot-israel-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Prasugrel Oral Tablet","genericName":"Prasugrel Oral Tablet","slug":"prasugrel-oral-tablet","indication":"Acute coronary syndrome (ACS) including unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI) managed with percutaneous coronary intervention (PCI)","status":"marketed"}]}],"pipeline":[{"name":"Prasugrel Oral Tablet","genericName":"Prasugrel Oral Tablet","slug":"prasugrel-oral-tablet","phase":"marketed","mechanism":"Prasugrel is a thienopyridine antiplatelet agent that irreversibly inhibits the P2Y12 adenosine diphosphate receptor on platelets, preventing platelet aggregation and thrombosis.","indications":["Acute coronary syndrome (ACS) including unstable angina, non-ST elevation myocardial infarction (NSTEMI), and ST elevation myocardial infarction (STEMI) managed with percutaneous coronary intervention (PCI)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxPM2NRYmwyVzBLNm9fT0NSU2dtZ0RtZHEtSTI0UUpDdzRmemN4ejJSSlFqU1NnaVVJeXNNTDUwM2xsSTQ2ekZWTTQwTXgzaUxLc3lKQXo3aHhJNnJfSUVDNVUzeE82b25xWm5IbjlVMVdyR1l0dTNHb3JhNDY3NDkzN08tUHhoNTVNTktsOGdMRkZGNHZkclRqRS1lUUtKQUJrUFdSQWlsU0tTQ3JJcks0Y3YwWnNWZjZES2xQZHNPMXVQeHdDZ25NZ0Nn?oc=5","date":"2024-05-09","type":"pipeline","source":"Healio","summary":"PCORI issues award to support asthma research comparing MART, PARTICS therapies - Healio","headline":"PCORI issues award to support asthma research comparing MART, PARTICS therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE9UVkNvb1JCTFUxUlBfbkpWeHN2dXctTkRQemYzUnZlY044QUlrcmhHQ1FMeUhaNERvYUJIdlZPa3NnaU45cmdHaEQwa1k4ZjYtc0luSTZxQ2tTSG9jWk9fWg?oc=5","date":"2022-02-27","type":"pipeline","source":"NEJM","summary":"Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma - NEJM","headline":"Reliever-Triggered Inhaled Glucocorticoid in Black and Latinx Adults with Asthma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE1UOUVmWTJNNHNPaUx5Z2dKSUg2TTRwY1BVaXF2V0Y3LUJRU05BbXUyWVM3UW9scGFCa3dCSWFBT2RkNjB2N1VBeXNSejNRa2l2V2Zjd25oVjlORGJqbFhKUQ?oc=5","date":"2021-05-12","type":"pipeline","source":"NEJM","summary":"Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma - NEJM","headline":"Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFB3anhod2JGbzFfNFgxNko0M0NKXzZhSkN6alBuM0xsdWxYdHZmQjNOclprdy1weUR2VHRlSVhnUXE1dGYzY2lkT1d2X1ZjbFplUWdiZllIeko3UEN1MURj?oc=5","date":"2018-06-28","type":"pipeline","source":"NEJM","summary":"KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma - NEJM","headline":"KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE9ncGROOThia21taGNVUE5lWk83cEtoakRhY1pEaVNHcU8waXZlZnFhYWM0Y051TTVtcm9HMzBzNmtZME91My1xVmlxWHpjV2s2VmRhNVRSMDZTM2VmYTh1WDRBLWxaUmNj?oc=5","date":"1996-09-19","type":"pipeline","source":"NEJM","summary":"Comparison of Regularly Scheduled with As-Needed Use of Albuterol in Mild Asthma - NEJM","headline":"Comparison of Regularly Scheduled with As-Needed Use of Albuterol in Mild Asthma","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}